# ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)

Study · id `cardio:ct-nct03682692` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03682692](<https://clinicaltrials.gov/study/NCT03682692>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03682692

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 560 participants.

## Technical summary

Registry record NCT03682692. Randomized; single masking; primary purpose treatment. Start 2018-06-01 (actual); primary completion 2021-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 560 participants (enrolled count; ClinicalTrials.gov record NCT03682692, source copy `cardio:ctgov-nct03682692-2023-02-14`, retrieved 2026-10-26)
- Started: 2018-06-01 (actual) (ClinicalTrials.gov record NCT03682692, source copy `cardio:ctgov-nct03682692-2023-02-14`, retrieved 2026-10-26)
- Primary completion: 2021-06-30 (actual) (ClinicalTrials.gov record NCT03682692, source copy `cardio:ctgov-nct03682692-2023-02-14`, retrieved 2026-10-26)
- Completion: 2022-03-31 (actual) (ClinicalTrials.gov record NCT03682692, source copy `cardio:ctgov-nct03682692-2023-02-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03682692, source copy `cardio:ctgov-nct03682692-2023-02-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03682692-2023-02-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)
- Condition: Hypertension
- Intervention (Drug): ACEI/CCB
- Intervention (Drug): ACEI/DIU
- Lead sponsor: Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-jiao-tong-university-school-of-medicine`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Comparison of two single-pill dual combination antihypertensive therapies in Chinese patients: a randomized, controlled trial (`cardio:pubmed-38263021`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antihypertensive treatment effect of two dual therapies according to sodium sensitivity (`cardio:pubmed-41053442`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 7b22d71dad53aabfd502e0bbc210afab1ec2b9afc2dc1051a3f839343567be76
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
